Multidisciplinary Strategies to Manage Treatment-Related Dermatologic Toxicity and Improve Quality of Life in Cancer...

Dermatologic toxicities are among the most common adverse effects of anticancer therapies, including chemotherapy, targeted therapies, and immunotherapies. Although typically non-life-threatening, these conditions can significantly impair quality of life, alter body image, and lead to treatment non-adherence which may compromise health outcomes. This systematic review aims to synthesize the evidence on the incidence, severity, and management of treatment-related dermatologic toxicities, with a focus on pharmaceutical and multidisciplinary care strategies.

This review followed the PRISMA 2020 guidelines. PubMed, ScienceDirect, and Cochrane were searched for studies published between 1 January 2015 and 31 December 2025. Eligibility criteria were defined using the PICO (R) framework. Study selection, data extraction, and risk-of-bias assessment were performed independently by two reviewers. Given study heterogeneity, a narrative synthesis was conducted.

Seventeen studies were included. Dermatologic toxicities were frequently reported during cancer treatment and were generally mild to moderate in severity, although they imposed a substantial burden on patients. Supportive dermatologic care strategies were associated with reduced symptom severity and improved quality of life in some studies. Evidence for pharmaceutical care and multidisciplinary management was more limited, and the available data do not allow firm conclusions regarding their effectiveness.

Dermatologic toxicities remain an important challenge in oncological care. The evidence suggests potential benefits of supportive care approaches, but the certainty of the evidence is limited, particularly for pharmaceutical care. Further high-quality studies are needed to clarify the impact of these interventions and support standardized recommendations.